Table 4.
PRCA in patients with and without STAT3 mutations
| PRCA with STAT3 mutation, n = 15 | PRCA without STAT3 mutation, n = 14 | P | |
|---|---|---|---|
| Age, median (range), y | 63 (20-74) | 73 (48-82) | .026* |
| Male, n (%) | 3 (20) | 5 (36) | .43 |
| WBC, median (range), ×109/L | 4.31 (2.25-19.1) | 4.73 (2.88-10.9) | .81 |
| Neutrophils, median (range), ×109/L | 1.57 (0.67-13.2) | 2.92 (0.72-8.74) | .13 |
| Lymphocytes, median (range), ×109/L | 2.83 (0.50-7.50) | 1.50 (0.31-4.12) | .044* |
| CD8+ T cells, median (range), ×109/L | 2.30 (0.22-5.51) | 0.34 (0.20-3.33) | .0034* |
| Hemoglobin, median (range), g/L | 75 (42-100) | 62 (40-92) | .045* |
| Reticulocytes, median (range), ×109/L | 15.9 (0-27.8) | 7.3 (2.3-16.7) | .13 |
| Platelets, median (range), ×109/L | 295 (113-584) | 300 (168-426) | .62 |
| LD, median (range), IU/L | 198 (159-350) | 193 (137-351) | .74 |
| Erythroblasts in BM, median (range), % | 1.2 (0.2-4.3) | 0.6 (0-5.2) | .53 |
| TCRγ monoclonality | 11/15 | 3/14 | .0092* |
| Skewed TCRβ repertoire | 9/10 | 0/6 | .00087* |
| Refractory to CsA | 9/13† | 0/8 | .0046* |
*
Significantly different.
†
Seven patients were refractory to CsA, and 2 became secondarily resistant to CsA.